OBJECTIVES: This study examined the risk of proarrhythmic events in patients receiving antiarrhythmic drugs for treatment of atrial fibrillation (AF) according to present-day safety guidelines. BACKGROUND: Advances in understanding the proarrhythmic risk of antiarrhythmic drugs has led to development of safety guidelines for these agents. Such guidelines were used in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. METHODS: This study was an analysis of the risk of arrhythmic events (arrhythmic death, resuscitated cardiac arrest, sustained ventricular tachycardia (VT), and torsade de pointes VT) in the antiarrhythmic drug arm of the AFFIRM study. Each time an antiarrhythmic drug was begun, it was counted as an exposure to that drug and the risk of an arrhythmic event was calculated. RESULTS: A total of 2,033 patients received 3,030 exposures to antiarrhythmic drugs. Ninety-six arrhythmic events occurred by six years. Patients with a left ventricular ejection fraction <40% had more arrhythmic events. Twelve documented cases of torsade de pointes VT were noted. The incidence of torsade de pointes was 0.6% at five years (95% confidence interval 0.32 to 1.07). CONCLUSIONS: The overall risk of adverse arrhythmic events upon exposure to antiarrhythmic drugs in the AFFIRM study was reasonably low. Strict criteria for the safe use of antiarrhythmic drugs were successful in minimizing proarrhythmic events.
OBJECTIVES: This study examined the risk of proarrhythmic events in patients receiving antiarrhythmic drugs for treatment of atrial fibrillation (AF) according to present-day safety guidelines. BACKGROUND: Advances in understanding the proarrhythmic risk of antiarrhythmic drugs has led to development of safety guidelines for these agents. Such guidelines were used in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. METHODS: This study was an analysis of the risk of arrhythmic events (arrhythmic death, resuscitated cardiac arrest, sustained ventricular tachycardia (VT), and torsade de pointes VT) in the antiarrhythmic drug arm of the AFFIRM study. Each time an antiarrhythmic drug was begun, it was counted as an exposure to that drug and the risk of an arrhythmic event was calculated. RESULTS: A total of 2,033 patients received 3,030 exposures to antiarrhythmic drugs. Ninety-six arrhythmic events occurred by six years. Patients with a left ventricular ejection fraction <40% had more arrhythmic events. Twelve documented cases of torsade de pointes VT were noted. The incidence of torsade de pointes was 0.6% at five years (95% confidence interval 0.32 to 1.07). CONCLUSIONS: The overall risk of adverse arrhythmic events upon exposure to antiarrhythmic drugs in the AFFIRM study was reasonably low. Strict criteria for the safe use of antiarrhythmic drugs were successful in minimizing proarrhythmic events.
Authors: Vincent E Hagens; Dirk J Van Veldhuisen; Harry J G M Crijns; Isabelle C van Gelder Journal: Ann Noninvasive Electrocardiol Date: 2006-04 Impact factor: 1.468
Authors: T Kleemann; T Becker; K Dönges; M Vater; B Gut; S Schneider; J Senges; K Seidl Journal: Clin Res Cardiol Date: 2006-11-24 Impact factor: 5.460
Authors: Nasir Shariff; Ravi V Desai; Kanan Patel; Mustafa I Ahmed; Gregg C Fonarow; Michael W Rich; Inmaculada B Aban; Maciej Banach; Thomas E Love; Michel White; Wilbert S Aronow; Andrew E Epstein; Ali Ahmed Journal: Am J Med Date: 2013-10 Impact factor: 4.965
Authors: Nicklas Vinter; Anne Sofie Frederiksen; Andi Eie Albertsen; Gregory Y H Lip; Morten Fenger-Grøn; Ludovic Trinquart; Lars Frost; Dorthe Svenstrup Møller Journal: Open Heart Date: 2020-06
Authors: Valentina A Rossi; Iva Krizanovic-Grgic; Jan Steffel; Daniel Hofer; Thomas Wolber; Corinna B Brunckhorst; Frank Ruschitzka; Firat Duru; Alexander Breitenstein; Ardan M Saguner Journal: Cardiol J Date: 2022-03-14 Impact factor: 3.487
Authors: Pattara Rattanawong; Win Shen; Hicham El Masry; Dan Sorajja; Komandoor Srivathsan; Arturo Valverde; Luis R Scott Journal: J Am Heart Assoc Date: 2020-06-09 Impact factor: 5.501